Safety update on dapagliflozin (DAPA) across the phase 2b/3 clinical trial program

Jabbour, Serge; Seufert, Jochen; SCHEEN, André; Bailey, Clifford; Karup, Kathrina; Langilde, Anna-Maria

Download

Poster (Scientific congresses and symposiums)

Safety update on dapagliflozin (DAPA) across the phase 2b/3 clinical trial program

Jabbour, Serge; Seufert, Jochen; SCHEEN, André et al.

2017 • American Diabetes Association 77 th scientific sessions

Permalink
https://hdl.handle.net/2268/211867

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Jabbour_Safety update_ADA 2017 abstract.pdf

Author preprint (193.41 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

SGLT2-inhibitors; Safety and tolerability

Disciplines :

Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology

Author, co-author :

Jabbour, Serge

Seufert, Jochen

SCHEEN, André ; Centre Hospitalier Universitaire de Liège - CHU > Service de diabétologie, nutrition, maladies métaboliques

Bailey, Clifford

Karup, Kathrina

Langilde, Anna-Maria

Language :

English

Title :

Safety update on dapagliflozin (DAPA) across the phase 2b/3 clinical trial program

Publication date :

June 2017

Event name :

American Diabetes Association 77 th scientific sessions

Event organizer :

ADA

Event place :

San Diego, United States

Event date :

june 9-13, 2017

By request :

Yes

Audience :

International

Available on ORBi :

since 16 June 2017

Statistics

Number of views

207 (1 by ULiège)

Number of downloads

111 (0 by ULiège)

More statistics